This video summarises the 12 month interim results from the RAINBOW study, an, ongoing, observational prospective study with a duration of 4 years, which explored the efficacy and safety of intravitreal aflibercept, as a first-line therapy in treatment naive patients with wet AMD, in a real-life setting in France (Sunday 11 September 2016, Free Paper Session 29). A preliminary analysis was performed on 132 eyes where patients received at least 1 injection after 12 months of follow up. The time to first injection following diagnosis of wet AMD was 18 days. Mean number of injections over the course of the 12 months was 6.1 and 91% of patients that received aflibercept at the loading phase was within the 112 days. Mean change in best corrected visual acuity at Month 12 was 6.7 letters and 7.2 letters in patients who received a loading phase. 14% of patients experienced at least one adverse event (AE); the most common were pain and ischemic attack, hospitalisation and one case of sudden death – none were declared drug-related. This interim analysis shows that sustained visual and anatomical improvements are evident in treatment-naive patients with wet AMD who received aflibercept bi-monthly over 12 months, and that the AEs were consistent with the known safety profile of aflibercept, showing that bimonthly aflibercept following the initial loading phase, is effective in a real-life setting

Related Articles